Hypnosis, placebos, and systematic research bias in biological psychiatry

American Journal of Clinical Hypnosis

Volumn 50, Issue 1, 2007, Pages 37-47

  Hammond, D Corydon ^a  

^a NONE   (United States)

Author keywords

Biological psychiatry; Hypnosis; Neurofeedback; Placebo; Psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATROPINE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ACUPUNCTURE; ANTICHOLINERGIC SYNDROME; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL PRACTICE; COGNITIVE THERAPY; COMPULSION; DEPRESSION; DRUG MANUFACTURE; EXPECTANCY; FEEDBACK SYSTEM; FINANCIAL MANAGEMENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPNOSIS; IMPOTENCE; INDUSTRIALIZATION; LIBIDO; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH; OUTCOME ASSESSMENT; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RATING SCALE; RELIABILITY; REVIEW; SEDATION; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SYSTEMATIC ERROR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

BIAS (EPIDEMIOLOGY); BIOLOGICAL PSYCHIATRY; DRUG INDUSTRY; HUMANS; HYPNOSIS; PLACEBO EFFECT; RESEARCH;

EID: 34347346130     PISSN: 00029157     EISSN: 21600562     Source Type: Journal    
DOI: 10.1080/00029157.2007.10401596     Document Type: Article

References (56)

1. Abramowitz, J. (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. Journal of Consulting & Clinical Psychology, 65. 44-52.
2. Ackerland, D. L., & Greenland, S. (2002). Multivariate meta-analysis of controlled drug studies of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 22(3), 309-317.
3. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy & Psychosomatics, 68. 3-14.
4. Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004). The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? American Journal of Psychiatry, 161 (12). 2163-2177.
5. Baxter, L., Schwartz, J. M., Bergman, K. S., Szuba, M. P., Guze, B. H., Mazziotta, J. C., Alazraki, A., Selin, C. E., Ferng H-W., Mumford, P., & Phelps, M. E. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry, 49, 681-688.
6. Brody, A. L., Saxena, S., Schwartz, J. M., Stoessel, P. W., Maidment, K., Phelps, M. E., & Baxter, L. R. (1998). FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. PsychiatryJ Research, 84. 1-6.
7. DeRubeis, R. J., Gelfand, L. A., Tang, T. Z., & Simons, A. D. (1999). Medications versus cognitive behavior therapy for severely depressed outpatients: Meta-analysis of four randomized comparisons. American Journal of Psychiatry, 156. 1007-1013.
8. Drug Effectiveness Review Project (2005). Drug class review on pharmacologic treatments for ADHD. Portland. OR: Oregon Health & Science University. Retrieved November 2005 from http://ww.ohsu.edu/drugeffectivensss/reports/doc ii ments/adhd_20FinaI_20Report.pdf.
9. Elkin, I., Shea, T., Watkins, J. T., Imber, S. D., Sotsky, S. M., Collins, J. F., et al. (1989). National Institute of Mental Health treatment of depression collaborative research program: General effectiveness of treatments. Archives of General Psychiatry, 46. 971-982.
10. El-Zein R. A., Abdel-Rahman, S.Z., Hay M. J., Lopez M.S., Bondy M.L., Morris D. L. & Legator, M. S. (2005). Cytogenetic effects in children treated with methylphenidate. Cancer Letters, 230(2). 284-291.
11. Freemantle, N., Anderson, I. M., & Young, P. (2000). Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis. British Journal of Psychiatry', 177. 292-302.
12. Goodman, W. K., McDougle, C. J., & Price, L. H. (1992). Pharmacotherapy of obsessive compulsive disorder. Journal of Clinical Psychiatryi, 53(Suppl), 29-37.
13. Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under "blinder'' conditions. Journal of Consulting & Clinical Psychology, 60.664-669.
14. Greenberg, R. P. & Fisher, S. (1989). Examining antidepressant effectiveness: Findings, ambiguities, and some vexing puzzles. In S. Fisher, R. P. Greenberg (Eds.). The limits of biological treatment for psychological distress: Comparisons with psychotherapy and placebo (pp. 1-37). Hillsdale. NJ: Erlbaum.
15. Greist, J. H. (1990). Treatment of obsessive compulsive disorder: Psychotherapies, drugs, and other somatic treatment. Journal of Clinical Psychiatry, 51(8), 44-50.
16. Hammond, D. C. (2007). Review of the efficacy of clinical hypnosis with headaches and migraine. International Journal of Clinical & Experimental Hypnosis, 55(2). 207-219.
17. Hilgard, E. R., & Hilgard, J. R. (1983). Hypnosis in the relief of pain (2nd edition). Los Altos. CA: William Kaufmann.
18. Hollon, M. F. (2005). Direct-to-consumer advertising: A haphazard approach to health promotion. Journal of the American Medical Association, 293(16). 2030-2033.
19. Hollon, S. D., DeRubeis, R. J., Evans, M. D., Wiemer, M. J., Garvey, M. J., Grove, W. M., et al. (1992). Cognitive therapy and pharmacotherapy for depression: Singly and in combination. Archives of Genera! Psychiatry, 49.774-781.
20. Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Weiss, B. (2002). The emperor's new drugs: Effect size and moderation effects. Prevention & Treatment, 5(27). Retrieved January 21.2003 from http://www.journals.apa.org/prevention/volume5/pre0050027c.html.
21. Hollon, S. D., Shelton, R. C., & Loosen, P. T. (1991). Cognitive therapy and pharmacotherapy for depression. Journal of Consulting & Clinical Psychology, 59, 88-99.
22. Jackson, G. E. (2005). Rethinking psychiatric drugs: A guide for informed consent. Bloomington, IN: Authorhouse.
23. Joughin, C., & Zwi, M. (1999). Focus on the use of stimulants in children with attention deficit hyperactivity disorder: Primary evidence-based briefing No. 1. London: Royal College of Psychiatrists Research Unit.
24. Khan, A., Khan, S., & Brown, W. A. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics? International Journal of Neuropsychopharmacology, 5, 193-197.
25. Kirsch I. (2005). Medication and suggestion in the treatment of depression. Contemporary Hypnosis, 22(2), 59-66.
26. Kirsch I. (2002). Yes, there is a placebo effect, but is there a powerful antidepressant drug effect? Prevention & Treatment, 5. Article 22. Retrieved Date from http://www.journals.apa.org/prevention.
27. Kirsch I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submnitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5, Article 23. Retrieved January 21, 2003 from http://www.journals.apa.org/prevention.
28. Kirsch I., & Sapperstein, G. (1998). Listening to Prozac, but hearing placebo? A metaanalysis of antidepressant medication. Prevention & Treatment, 1. Retrieved January 21. 2003 from http://www.journals.apa.org/prevention.
29. Klein, D. F. (1998). Listening to meta-analysis blit hearing bias. Prevention & Treatment, I. Retrieved January 21, 2003 from http://www.journals.apa.org/prevention.
30. Knox, V. J., Gekoski, W. L., Shum, K., & McLaughlin, D. M. (1981). Aanalgesia for experimentally induced pain: Multiple sessions of acupuncture compared to hypnosis in high-and low-susceptible subjects. Journal of Abnormal Psychology, 90, 28-34.
31. La Vaque, T. J., & Rossiter, T. (2001). The ethical use of placebo controls in clinical research: the Declaration of Helsinki. Applied Psychophysiology & Biofeedback, 26(1), 23-37.
32. Lambert, M. J., & Ogles, B. M. (2004). The efficacy and effectiveness of psychotherapy. In M. J. Lambert (Ed.), Handbook of psychotherapy and behavior change (5th Edition; pp. 139-193). New York: Wiley.
33. Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., & Abrams, M. (2002). Change in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry, 159, 122-129.
34. Li, J. H., Hu, H. C., Chen, W. B., & Lin, S. K. (2003). Genetic toxicity of methamphetamine in vitro and in human abusers. Environmental & Molecular Mutagenesis, 42, 233-242.
35. Mayberg, H. S., k Silva, J. A., Brannan, S. K., Teckell, J. L., Mahurin, R. K., & McGinnis, S. (2002). The functional neuroanatomy of the placebo effect. American Journal of Psychiatry, 159, 728-737.
36. McGlashan, T. H., Evans, F. J., & Orne, M. T. (1969). The nature of hypnotic analgesia and placebo response to experimental pain. Psychosomatic Medicine, 31(3), 227-246.
37. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326. 1171-1173.
38. Miller, M. E., & Bowers, K. S. (1986). Hypnotic analgesia and stress inoculation training in the reduction of pain. Journal of Abnormal Psychology, 95. 6-14.
39. Monastra, V. J. (2005). Electroencephalographic biofeedback (neurotherapy) as a treatment for attention deficit hyperactivity disorder: Rationale and empirical foundation. Child & Adolescent Psychiatric Clinics ofNoilh America, 14(1), 55-82.
40. Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials. Journal of Nervous & Mental Disease, 189(5), 288-295.
41. Moncreiff, J. (2002). The antidepressant debate. British Journal of Psychiatry, 180. 193-194.
42. Moncrieff, J. (2003). A comparison of antidepressant trials using active and inert placebos. International Journal of Methods in Psychiatric Research, 12(3), 117-127.
43. Moncrieff, J., & Cohen, D. (2005). Rethinking models of psychotropic drug action. Psychotherapy & Psychosomatics, 74.145-153.
44. Moncrieff, J., & Kirsch I. (2005). Efficacy of antidepressants in adults. British Medical Journal, 331.155-157.
45. Montcrieff, J., Wessely, S., & Hardy, R. (1998). Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry, 172, 227-231.
46. Montgomery, G H., DuHamel, K. N., & Redd, W. H. (2000). A meta-analysis of hypnotically induced analgesia: How effective is hypnosis? International Journal of Clinical & Experimental Hypnosis, 48(2). 138-153.
47. Olfson, M., Marcus, S. C., Dmss, B., Elinson, L., Tanielian, T., & Rincus, H. A. (2002). National trends in the outpatient treatment of depression. Journal of the American Medical Association, 287, 203-209.
48. Rabkin, J. G., Markowitz, J. S., Stewart, J. W., McGrath, P. J., Harrison, W., Quitkin, F. J., & Klein, D. F. (1986). How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research, 19, 75-86.
49. Raz, A. (2007). Hypnobo: Perspectives on hypnosis and placebo. American Journal of Clinical Hypnosis. 50(1), 29-36.
50. Schächter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal, 165(11), 1475-1488.
51. Schwartz, J. M., Stoessel, P. W., Baxter, L. R., Martin, K. M., & Phelps, M. E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 53. 109-113.
52. Stem, J. A., Brown, M., Ulett, G A., & Sletten, I. (1977). A comparison of hypnosis, acupuncture, morphine, valium, aspirin, and placebo in the management of experimentally-induced pain. In W. E. Edmonston (Ed.). Conceptual and investigative approaches to hypnosis and hypnotic phenomena. Annals of the New York Academy of Sciences, 296, 175-193.
53. Stevens, S. E., Hyman, M. T., & Allen, M. (2000). A meta-analysis of common factor and specific treatment effects across domains of the phase model of psychotherapy. Clinical Psychology: Science & Practice, 7, 273-290.
54. Suffin, S. C., & Emory, W. (1995). Neurometric subgroups in attentional and affective disorders and their association with pharmacotherapeutic outcome. Clinical Electroencephalography, 26(2). 76-83.
55. Wyatt, W. J., & Midkiff, D. M. (2006). Biological psychiatry: A practice in search of a science. Behavior & Social Issues, 15. 132-151.
56. Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry', 159(3), 469-473.